Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

HCW Biologics Inc. HCWB NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score
23/100
1/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

HCW Biologics Inc. (HCWB) is a Biotechnology company in the Healthcare sector, currently trading at $0.35. It has a SharesGrow Score of 23/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Valuation: HCWB trades at a trailing Price-to-Earnings (P/E) of -0.1 (S&P 500 average ~25).

Financials: revenue is $54,232, -55.1%/yr average growth. Net income is $22M (loss), growing at -21.4%/yr. Net profit margin is -41117.2% (negative). Gross margin is 20% (-18.5 pp trend).

Balance sheet: total debt is $7M against $3M equity (Debt-to-Equity (D/E) ratio 2.46, leveraged). Current ratio is 0.11 (tight liquidity). Debt-to-assets is 27.8%. Total assets: $25M.

Analyst outlook: 3 / 3 analysts rate HCWB as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 0/100 (Fail), Moat 14/100 (Fail), Future 100/100 (Pass), Income 10/100 (Fail).

HCWB SharesGrow Score Overview

35/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 0/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 14/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — HCWB

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
HCWB: -55.1%/yr revenue is, -21.4%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
—
HEALTH N/A
N/A
No analyst coverage available for this stock.
✗
MOAT Fail
14/100
HCWB: Gross margin is 20% (-18.5 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 14/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 3 / 3 analysts rate HCWB as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
HCWB: Net profit margin is -41117.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.25-17.8
Volume163.95K
Avg Volume (30D)8.5M
Market Cap$721.7K
Beta (1Y)0.79
Share Statistics
EPS (TTM)-10.63
Shares Outstanding$2.1M
IPO Date2021-07-20
Employees36
CEOHing C. Wong
Financial Highlights & Ratios
Revenue (TTM)$54.23K
Gross Profit$10.85K
EBITDA$-13.16M
Net Income$-22.3M
Operating Income$-13.16M
Total Cash$1.95M
Total Debt$6.81M
Net Debt$4.86M
Total Assets$24.52M
Price / Earnings (P/E)-0
Price / Sales (P/S)13.31
Analyst Forecast
Rating ConsensusBuy
Analysts Covering3
Buy 100% Hold 0% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Market
CurrencyUSD
ISINUS40423R2040

Price Chart

Track all markets on TradingView
HCWB
HCW Biologics Inc. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
0.25 52WK RANGE 17.80

People Also View

PHVS
PHVS
Pharvaris N.V.
$28.68
+2.87%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 RZLT
RZLT
Rezolute, Inc.
$3.56
-1.36%
 STTK
STTK
Shattuck Labs, Inc.
$6.78
+0.15%
 IPSC
IPSC
Century Therapeutics, Inc.
$2.37
+4.41%
 MOLN
MOLN
Molecular Partners AG
$4.14
-1.66%
 PRDS
PRDS
Pardes Biosciences, Inc.
$2.18
+0.93%
 PEPG
PEPG
PepGen Inc.
$1.69
+0.59%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message